Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2002-12-23
2010-10-26
Channavajjala, Lakshmi S (Department: 1611)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C514S717000, C514S725000, C514S772000
Reexamination Certificate
active
07820186
ABSTRACT:
Dermatological/cosmetic gel compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise (i) at least one retinoid, (ii) dispersed benzoyl peroxide and (iii) at least one pH-independent gelling agent, formulated into (iv) a physiologically acceptable medium therefor.
REFERENCES:
patent: 4189501 (1980-02-01), Fulton, Jr.
patent: 4717720 (1988-01-01), Shroot et al.
patent: 4792452 (1988-12-01), Howard et al.
patent: 4960772 (1990-10-01), Sebag et al.
patent: 5035890 (1991-07-01), Braun
patent: RE34440 (1993-11-01), Shroot et al.
patent: RE34805 (1994-12-01), Shroot et al.
patent: 5690946 (1997-11-01), Koulbanis et al.
patent: 5707635 (1998-01-01), Deckner et al.
patent: 5733886 (1998-03-01), Baroody et al.
patent: 5824650 (1998-10-01), De Lacharriere et al.
patent: 6106848 (2000-08-01), Preuilh et al.
patent: 6274151 (2001-08-01), Michel et al.
patent: 6423324 (2002-07-01), Murphy et al.
patent: 2002/0035161 (2002-03-01), Segura et al.
patent: 2002/0064541 (2002-05-01), Lapidot et al.
patent: 2003/0033678 (2003-02-01), Wiesche et al.
patent: 2005/0181999 (2005-08-01), Ferrandis et al.
patent: 2006/0233735 (2006-10-01), Preuilh et al.
patent: 1072843 (1992-10-01), None
patent: 0 335 115 (1989-10-01), None
patent: 2 378 523 (1978-08-01), None
patent: 2 618 673 (1989-02-01), None
patent: 2 628 319 (1989-09-01), None
patent: 2 753 626 (1998-03-01), None
patent: 2 833 841 (2003-06-01), None
patent: 1 594 314 (1981-07-01), None
patent: 2 207 353 (1989-02-01), None
patent: 218592 (1996-06-01), None
patent: 218936 (1997-02-01), None
patent: 1 100 134 (1989-04-01), None
patent: 1 268 632 (1989-10-01), None
patent: 7 500 593 (1995-01-01), None
patent: 93/07856 (1993-04-01), None
patent: WO 93/07856 (1993-04-01), None
patent: WO 95/31978 (1995-11-01), None
patent: 99/65456 (1999-12-01), None
patent: WO 00/37027 (2000-06-01), None
patent: WO 01/45647 (2001-06-01), None
patent: WO 03/055472 (2003-07-01), None
patent: WO 2007/002831 (2007-01-01), None
patent: WO 2008/006888 (2008-01-01), None
Mills Jr. et al. Comparing 2.5%, 5% and 10% benzoyl peroxide on inflammatory acne vulgaris. Int. J. Dermatology. Dec. 1986, 25(10);664-667.
Caron et al.. “Skin Tolerance of Adapalene 0.1% Gel in Combination with other Topical Antiacne Treatments” Journal of the American Academy of Dermatology, vol. 36. No. 6. Part 2, 1997. pp. S113-S115.
Martin et al., “Chemical Stability of Adapalene and Tretinoin when combined with Benzoyl Peroxide in Presence and in Absence of Visible Light and Ultraviolet Radiation”, British Journal of Dermatology, vol. 139. No. S52. 1998. pp. 8-11.
Hurwitz. “The Combined Effect of Vitamin A Acid and Benzoyl Peroxide inthe Treatment of Acne”. vol. 17. No. 3 Mar. 1976. pp. 585-590.
Search Report issued for FR 01/016747 on Sep. 4, 2002. 3 pages.
Chellquist et al., “Benzoyl Peroxide Solubility and Stability in Hydric Solvents,”Pharmaceutical Research, vol. 9, No. 10, 1992, pp. 1341-1346, published by Springer, The Netherlands.
Seppic Personal Care Ingredients Catalog, pp. 1-26 and endnotes, 2004/rev. 2006, published by SEPPIC S.A., Lyon, France.
Bershard, S.V., “The modem age of acne therapy: a review of current treatment options,” Mt Sinai J Med Sep.-Oct. 2001; 68(4-5); 279-86.
Bikowski, “Clinical Experience Results with Clindamycin 1% Benzoyl Peroxide 5% Gel (Duac®) as Monotherapy and in Combination”, Journal of Drugs in Dermatology, Mar. 2005, pp. 164-171, vol. 4, No. 2.
Brand et al., “Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents”, J. Am. Acad. Dermatol., Sep. 2003, pp. S227-S232, vol. 49, No. 3, Cranbury, NJ.
Capizzi, et al., “Efficacy and Safety of Combination Therapy of Hydrogen Peroxide Cream and Adapalene Gel in Comparison with Benzoyl Peroxide Cream and Adapalene in Common Acne,” Journal of the American Academy of Dermatology, vol. 50, Issue 3, Supplement 1, p. P18 (Mar. 2004).
Capizzi et al., “Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator-masked, controlled trial”, British Journal of Dermatology, 2004, pp. 481-484, vol. 151, No. 2.
Clucas et al., “Adapalene 0.1% gel has low skin irritation potential”, Journal of the European Academy of Dermatology and Venereology, Sep. 1998, p. S275, vol. 11, Elsevier Science Publisher.
Gollnick et al., “Evaluation of a maintenance treatment of acne vulgaris with adapalene gel 0.1%”, Journal of the American Academy of Dermatology, Mar. 2005, p. P18, vol. 52, No. 3.
Korkut et al., “Benzoyl Peroxide, Adapalene, and their Combination in the Treatment of Acne Vulgaris”, The Journal of Dermatology, 2005, pp. 169-173, vol. 32, No. 3, Edirne, Turkey.
Leyden, James J., “A Review of the Use of Combination Therapies for the Treatment of Acne Vulgaris,” Journal of the American Academy of Dermatology, vol. 49, No. 3, pp. S200-S210 (Sep. 2003).
Leyden, et al., “Photographic Review of Results From a Clinical Study Comparing Benzoyl Peroxide 5%/Clindamycin 1% Topical Gel with Vehicle in the Treatment of Rosacea,” Topical Treatment for the Inflamed Lesion in Acne, Rosacea, and Pseudofolliculitis Barbae, Jun. 2004, vol. 73, p. 3.
Relyveld et al., “Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: A randomized study,” J. Am. Acad. Dermatol., Nov. 2006, vol. 55, No. 5, pp. 836-843.
Van Zuuren, et al., “Systematic review of rosacea treatments,” J. Am. Acad. Dermatol., Jan. 2007, vol. 56, No. 1, pp. 107-115.
Weiss et al., “Adapalene for the treatment of acne vulgaris”, Journal of the American Academy of Dermatology, Aug. 1998, pp. S50-S54, vol. 39, No. 2.
Wen-Wen et al., “Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter randomized study”, Database Biosis, Biosciences Information Service, Jun. 2003, Database accession No. PREV200300514701, pp. 310-312, vol. 36, No. 6.
Co-pending U.S. Appl. No. 11/826,364, filed Jul. 13, 2007.
Co-pending U.S. Appl. No. 12/318,937, filed Jan. 13, 2009, continuation of Application No. PCT/EP2007/057207, filed on Jul. 12, 2007.
Co-pending U.S. Appl. No. 12/473,981, filed May 28, 2009, continuation-in-part of U.S. Appl. No. 12/318,937.
Office Action dated Dec. 29, 2009, in co-pending U.S. Appl. No. 11/826,364.
Office Action dated Oct. 21, 2009, in co-pending U.S. Appl. No. 12/318,937.
English language abstract of FR 2 833 841, Jun. 27, 2003.
International Search Report for PCT/EP2007/057207, dated Sep. 24, 2007.
International Search Report for EP 02799797, dated Mar. 24, 2003.
Walker, Susan J., M.D., “Summary Review” dated Dec. 1, 2008, NDA No. 22-320 (6 pages).
FDA label for Differin 0.1% gel, NDA No. 020380 (3 pages), Dec. 8, 2008.
Orsoni Sandrine
Willcox Nathalie
Channavajjala Lakshmi S
Finnegan Henderson Farabow Garrett & Dunner LLP
Galderma Research & Development
LandOfFree
Gel composition for once-daily treatment of common acne... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gel composition for once-daily treatment of common acne..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gel composition for once-daily treatment of common acne... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160537